Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vagifem Low for genitourinary symptoms in women with early breast cancer receiving aromatase inhibitors
ACTRN12620000955910Phase 2Active, not recruiting
- Sponsor
- University of Sydney
- Start
- Oct 2020
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estradiol in vaginal atrophy, sponsored by University of Sydney. Primary endpoint: Adherence to treatment with Vagifem Low. Started Oct 2020; status: active, not recruiting.
02
Drugs
estradiol
03
Conditions
vaginal atrophy
Beyond the preview
Go deeper on ACTRN12620000955910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000955910.